城郊高龄老年房颤患者华法林治疗的安全性

目的：探讨城郊高龄老年房颤患者应用华法林的安全性.方法：选择100例资料完整的老年房颤患者,按照数字表法,被随机分为华法林组（51例）：华法林起始剂量1.25 mg,1次/d.每隔3d测定血浆凝血酶原时间国际标准化比值（INR）1次.2～4周达到目标范围,如INR未达标,每隔1周增加华法林0.625 mg,直到INR控制在2.0～3.0.INR稳定前门诊随访每周监测1次,INR稳定后每4周监测1次;阿司匹林组（49例）：阿司匹林,100 mg,1次/d.结果：与阿司匹林组比较,华法林组血栓栓塞等终点事件发生率明显降低（19.15％比3.92％,P=0.017）,出血等不良反应发生率无显著差异（4.25％比5.88％,P＞0.05）.结论：高龄老年房颤患者应用华法林,能显著降低栓塞发生率,而且是安全的.

Safety of warfarin treatment in advanced aged patients with atrial fibrillation living in suburbs

Objective.. To explore the safety of warfarin in advanced aged patients with atrial fibrillation （AF） living in sub- urbs. Methods： A total of 100 aged AF patients with complete data were selected, according to number table method, they were ranaomly divided into warfarin group （n = 51, loading dose of warfarin was 1.25mg, once/d. International normal- ized ratio （INR） was measured every three days. ICR was expected to reach target range in 2-4 weeks, if INR didrft reach target, warfarin dose was increased by 0. 625mg every one week until INR was controlled in 2. 0-3.0. INR was monitored once/week on outpatient follow-up before it＇s stable, and once/4 weeks after it＇s stable） and aspirin group （n-- 49, received aspirin 100mg once/d）. Results： Compared with aspirin group, there was significant reduction in incidence rate of endpoint events （such as thromboembolism etc. ） （19.15% vs. 3. 92%, P = 0. 017） in warfarin group. But there was no significant difference in incidence rate of adverse reactions （such as hemorrhage etc. ） （4. 25% vs. 5. 88%, P〉0. 05） between aspirin group and warfarin group. Conclusion： Warfarin could significantly reduce the incidence rate of embolism and is safe in ad- vanced-aged patients with atrial fibrillation.